title: Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor.
abstract: The aim of our study was to explore whether nerve growth factor (NGF) plays any role in the development of peripheral neuropathy induced by anticancer treatment. We measured the circulating NGF levels in 23 cancer patients before and after chemotherapy. We evaluated whether the development of peripheral neurotoxicity was associated with changes in basal NGF concentrations in patients studied with a comprehensive neurological and neurophysiological examination. The results of these studies showed that the circulating levels of NGF, which are about 20 pg/ml in plasma of controls, decrease during chemotherapy and in some cases completely disappeared after prolonged treatment with antitumor agents. The decrease in NGF levels seems to be correlated with the severity of neurotoxicity. These results clearly suggest that NGF might become a useful agent to prevent neuropathies induced by antineoplastic drugs and restore peripheral nerve dysfunction induced by these pharmacological compounds.
authors.affiliation: Division of Medical Oncology, San Carlo Hospital, Potenza, Italy.
authors.forename: S
authors.initials: S
authors.lastname: De Santis
authors.forename: A
authors.initials: A
authors.lastname: Pace
authors.forename: L
authors.initials: L
authors.lastname: Bove
authors.forename: F
authors.initials: F
authors.lastname: Cognetti
authors.forename: F
authors.initials: F
authors.lastname: Properzi
authors.forename: M
authors.initials: M
authors.lastname: Fiore
authors.forename: V
authors.initials: V
authors.lastname: Triaca
authors.forename: A
authors.initials: A
authors.lastname: Savarese
authors.forename: M D
authors.initials: MD
authors.lastname: Simone
authors.forename: B
authors.initials: B
authors.lastname: Jandolo
authors.forename: L
authors.initials: L
authors.lastname: Manzione
authors.forename: L
authors.initials: L
authors.lastname: Aloe
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D015415:Biomarkers / Q000097:blood; D001943:Breast Neoplasms / Q000188:drug therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000188:drug therapy*; D009414:Nerve Growth Factors / Q000097:blood*; D009460:Neurologic Examination; D009475:Neurons, Afferent / Q000502:physiology; D010051:Ovarian Neoplasms / Q000188:drug therapy; D010292:Paresthesia / Q000139:chemically induced; D010523:Peripheral Nervous System Diseases / Q000097:blood* / Q000139:chemically induced* / Q000503:physiopathology; D010543:Peroneal Nerve / Q000503:physiopathology; D013497:Sural Nerve / Q000503:physiopathology
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers; D009414:Nerve Growth Factors